3-(substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same

Abstract

The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.

1 - 49 . (canceled) 
     
     
         50 . A method for treating a disorder selected from the group consisting of multiple myeloma, leprosy, and a non-Hodgkin’s lymphoma, in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a deuterium-enriched compound of formula IIIe or IIIf:
                     
                     
 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: 
 R 6  is selected from H, D, —(CH 2 ) n OH, phenyl, -O(C 1 -C 6 )alkyl, and (C 1 -C 6 )alkyl optionally substituted with one or more halo; 
 R 7  is selected from H, D, halo, —(CH 2 ) n OH, (C 1 -C 6 )alkyl optionally substituted with one or more halo, (C 1 -C 6 )alkoxy optionally substituted with one or more halo, and -(CH 2 ) n NHR a ; 
 R a  is selected from H, D, (C 1 -C 6 )alkyl optionally substituted with one or more halo, —(CH 2 ) n —(6 to 10 membered aryl), —C(O)(CH 2 ) n —(6 to 10 membered aryl), —C(O)(CH 2 ) n —(6 to 10 membered heteroaryl), -C(O)(C 1 -C 8 )alkyl optionally substituted with one or more halo, —C(O)(CH 2 ) n —(C 3 -C 10 -cycloalkyl), -C(O)(CH 2 ) n -NR b R c , —C(O)(CH 2 ) n —O—(C 1 -C 6 )alkyl, and —C(O)(CH 2 ) n —O—(CH 2 ) n —(6 to 10 membered aryl), wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halo, —SCF 3 , (C 1 -C 6 )alkyl optionally substituted with one or more halo, and (C 1 -C 6 )alkoxy optionally substituted with one or more halo; 
 R b  and R c  are each independently selected from H, D, (C 1 -C 6 )alkyl optionally substituted with one or more halo, (C 1 -C 6 )alkoxy optionally substituted with one or more halo, and 6 to 10 membered aryl, the aryl being optionally substituted with one or more groups independently selected from halo, (C 1 -C 6 )alkyl optionally substituted with one or more halo, and (C 1 -C 6 )alkoxy optionally substituted with one or more halo; 
 n is independently selected from 0, 1, and 2; and 
 a hydrogen atom present in any substituent is optionally replaced by D; 
 wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-D carbon, of at least 5%. 
 
     
     
         51 . The method of  claim 50 , wherein R 7  is selected from halo, CH 3 , OH, and CF 3 . 
     
     
         52 . The method of  claim 50 , wherein R 6  is H or CH 3 . 
     
     
         53 . The method of  claim 51 , wherein the deuterium-enriched compound is a compound of formula IIIe or IIIf
                                             and the compound is selected from the group consisting of:   a. R 6  = CH 3  and R 7  = CH 3 ;   b. R 6  = CH 3  and R 7  = F;   c. R 6  = CH 3  and R 7  = Cl;   d. R 6  = CH 3  and R 7  = Br;   e. R 6  = CH 3  and R 7  = OH;   f. R 6  = CH 3  and R 7  = CF 3 ;   g. R 6  = H and R 7  = CH 3 ;   h. R 6  = H and R 7  = CH 3 ;   i. R 6  = CD 3  and R 7  = CH 3 ;   j. R 6  = CD 3  and R 7  = F;   k. R 6  = CD 3  and R 7  = Cl;   l. R 6  = CD 3  and R 7  = Br;   m. R 6  = CD 3  and R 7  = OH;   n. R 6  = CD 3  and R 7  = CF 3 ;   o. R 6  = D and R 7  = CH 3 ;   p. R 6  = D and R 7  = CH 3 ;   q. R 6  = CH 3  and R 7  = CD 3 ;   r. R 6  = H and R 7  = CD 3 ;   s. R 6  = H and R 7  = CD 3 ;   t. R 6  = CD 3  and R 7  = CD 3 ;   u. R 6  = D and R 7  = CD 3 ; and   v. R 6  = D and R 7  = CD 3 ;   and pharmaceutically acceptable salts and solvates thereof.   
     
     
         54 . A method for treating a disorder selected from the group consisting of multiple myeloma, leprosy, and a non-Hodgkin’s lymphoma, in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a deuterium-enriched compound of formula Ia or Ib
                     
                     
 and pharmaceutically acceptable salts and solvates thereof, wherein: 
 Z is D; 
 R 1 , R 2 , R 3 , R 4 , R 5 , and R 10  are independently selected from H and D; 
 R 6  is selected from H, D, —(CH 2 ) n OH, phenyl, -O(C 1 -C 6 )alkyl, and (C 1 -C 6 )alkyl optionally substituted with one or more halo; 
 two of R 7 , R 8 , and R 9  are independently selected from halo, —(CH 2 ) n OH, (C 1 -C 6 )alkyl optionally substituted with one or more halo, and (C 1 -C 6 )alkoxy optionally substituted with one or more halo, and the remaining of R 7 , R 8 , and R 9  is H or D; or 
 alternatively, two of R 7 , R 8 , R 9 , and R 10  together form a 5-6 membered ring optionally substituted with one or more groups independently selected from halo, (C 1 -C 6 )alkyl optionally substituted with one or more halo, and (C 1 -C 6 )alkoxy optionally substituted with one or more halo, and the remaining of R 7 , R 8 , R 9 , and R 10  are H or D; 
 n is independently selected from 0, 1, and 2; and 
 a hydrogen atom present in any substituent is optionally replaced by D; 
 wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-Z carbon, of at least 5%. 
 
     
     
         55 . The method of  claim 54 , wherein the deuterium-enriched compound is selected from the group consisting of:
                                                                                                                                     and pharmaceutically acceptable salts and solvates thereof, wherein the compound has an enantiomeric excess, with respect to the C-D carbon, of at least 5%.   
     
     
         56 . The method of  claim 50 , wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-D carbon, selected from (a) at least 10%, (b) at least 20%, (c) at least 30%, (d) at least 40%, (e) at least 50%, (f) at least 60%, (g) at least 70%, (h) at least 80%, (i) at least 90%, (j) at least 95%, (k) at least 97%, (1) at least 98%, and (m) at least 99%. 
     
     
         57 . The method of  claim 50 , wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-D carbon, of at least 90%. 
     
     
         58 . The method of  claim 54 , wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-Z carbon, selected from (a) at least 10%, (b) at least 20%, (c) at least 30%, (d) at least 40%, (e) at least 50%, (f) at least 60%, (g) at least 70%, (h) at least 80%, (i) at least 90%, (j) at least 95%, (k) at least 97%, (1) at least 98%, and (m) at least 99%. 
     
     
         59 . The method of  claim 54 , wherein the deuterium-enriched compound has an enantiomeric excess, with respect to the C-D carbon, of at least 90%. 
     
     
         60 . The method of  claim 50 , wherein the disorder is multiple myeloma or a non-Hodgkin’s lymphoma. 
     
     
         61 . The method of  claim 60 , wherein the disorder is a non-Hodgkin’s lymphoma selected from the group consisting of diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. 
     
     
         62 . The method of  claim 54 , wherein the disorder is multiple myeloma or a non-Hodgkin’s lymphoma. 
     
     
         63 . The method of  claim 62 , wherein the disorder is a non-Hodgkin’s lymphoma selected from the group consisting of diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.